Sahajanand Medical Technologies Limited (SMT) announced its unaudited consolidated financial results for the quarter and half-year ended September 30, 2026. The company reported robust financial performance, alongside the approval of an investment in SNP Medical Corp., a US-based medical device startup. This strategic move signifies SMT’s intent to expand its product portfolio and geographical presence in the global medical device market. The Board also approved the appointment of M/s. Amit Jaste & Associates as the Secretarial Auditor for five financial years.
Sahajanand Medical Technologies Reports Q2 Financials and Strategic Growth Initiatives
Sahajanand Medical Technologies Limited (SMT) has publicly disclosed its unaudited consolidated financial results for the quarter and six-month period that concluded on September 30, 2026. The Board of Directors reviewed and approved these results during a meeting held on November 05, 2026.
Key Financial Highlights
The disclosed financial statements reveal the company’s performance for the specified periods. The unaudited consolidated results for the quarter and half-year ended September 30, 2026, along with the Limited Review Report, have been submitted to the stock exchanges. Detailed financial figures are available in the accompanying statements, indicating revenue from operations and profit before tax. For the six-month period ended September 30, 2026, the consolidated revenue from operations stood at ₹72,507.86 lacs, with a profit before tax of ₹4,006.87 lacs.
Strategic Acquisition of SNP Medical Corp
In a significant move to expand its business horizons, SMT has approved an investment in SNP Medical Corp., a US-based corporation registered in Delaware. This entity is a wholly-owned subsidiary of SMT’s existing subsidiary, Sahajanand Medical Technologies Ireland Limited. SNP Medical Corp. is described as a medical device startup focused on developing innovative medical devices. This acquisition is part of SMT’s strategy to diversify its product portfolio and strengthen its presence in the North American market. The acquisition cost is up to USD 7,80,000/-. SMT Ireland currently holds a 14.15% stake in SNP Medical Corporation, which is expected to increase to 17.19% post-acquisition.
Appointment of Secretarial Auditor
Further to the board meeting, M/s. Amit Jaste & Associates has been appointed as the Secretarial Auditor of the Company. This appointment is for a term of five consecutive financial years, commencing from FY 2026-27 to FY 2030-31, subject to shareholder approval. M/s. Amit Jaste & Associates is a firm of Practising Company Secretaries with over 22 years of experience in the field.
Disclosure and Availability
The company has ensured compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, by submitting all necessary details and annexures as required. The financial results and related information are also made available on the websites of the Bombay Stock Exchange (BSE), National Stock Exchange (NSE), and the company’s own website, www.smtpl.com.
Source: BSE
